Although still challenging, epigenetic-targeted therapeutic strategies are rapidly developing [81,82] and may open new avenues for restoring endogenous ATIP3 levels in ATIP3-deficient breast tumors. The gene discussed is MTUS1; the disease is breast neoplasm.